Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy

X
Trial Profile

A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naldemedine (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational
  • Acronyms COMPOSE III
  • Sponsors Shionogi
  • Most Recent Events

    • 12 Feb 2020 Integrated analysis of three phase 3 trials (COMPOSE-1, COMPOSE-2, and COMPOSE-3) published in the Drugs and Aging
    • 22 Feb 2019 According to a Shionogi media release, European Commission (EC) granted a Marketing Authorisation (MA) for Rizmoic (naldemedine), for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative, based on data from three phase 3 efficacy and safety studies (V9231, V9232 and V9236) and one long term safety study (V9235).
    • 18 Dec 2018 According to a Shionogi media release, based on data from three phase 3 efficacy and safety studies (V9231, V9232 and V9236) and one long term safety study (V9235), the CHMP has adopted a positive opinion recommending Rizmoic (naldemedine), for the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. The EC will issue a decision in due course for naldemedine, taking into account the recommendation from the CHMP.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top